CD101 and fungal infectious disease: CD101, a novel echinocandin being developed as a high-exposure, once-weekly intravenous (i.v.)formulation for the treatment and prevention of systemic fungal infections, was designed to be chemically and metabolically stable to avoid hepatotoxicity while retaining the antifungal activity of an echinocandin.